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2-(4-Aminophenyl)benzothiazoles represent a potent and highly selective class of antitumour agent. In vitro, sensitive carcinoma cells
deplete 2-(4-aminophenyl)benzothiazoles from nutrient media; cytochrome P450 1A1 activity, critical for execution of antitumour
activity, and protein expression are powerfully induced. 2-(4-Amino-3-methylphenyl)benzothiazole-derived covalent binding to
cytochrome P450 1A1 is reduced by glutathione, suggesting 1A1-dependent production of a reactive electrophilic species. In vitro,2 -
(4-aminophenyl)benzothiazole-generated DNA adducts form in sensitive tumour cells only. At concentrations 4100nM, adducts
were detected in DNA of MCF-7 cells treated with 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203). 5F 203 (1mM) led
to the formation of one major and a number of minor adducts. However, treatment of cells with 10mM 5F 203 resulted in the
emergence of a new dominant adduct. Adducts accumulated steadily within DNA of MCF-7 cells exposed to 1mM 5F 203 between 2
and 24h. Concentrations of the lysylamide prodrug of 5F 203 (Phortress) Z100nM generated adducts in the DNA of sensitive MCF-
7 and IGROV-1 ovarian cells. At 1mM, one major Phortress-derived DNA adduct was detected in these two sensitive phenotypes;
10mM Phortress led to the emergence of an additional major adduct detected in the DNA of MCF-7 cells. Inherently resistant MDA-
MB-435 breast carcinoma cells incurred no DNA damage upon exposure to Phortress (p10mM, 24h). In vivo, DNA adducts
accumulated within sensitive ovarian IGROV-1 and breast MCF-7 xenografts 24h after treatment of mice with Phortress
(20mgkg
 1). Moreover, Phortress-derived DNA adduct generation distinguished sensitive MCF-7 tumours from inherently resistant
MDA-MB-435 xenografts implanted in opposite flanks of the same mouse.
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Novel 2-(4-aminophenyl)benzothiazoles possess remarkably
selective antitumour properties (Shi et al, 1996; Bradshaw et al,
1998a,b) and represent a mechanistic class distinct from clinically
used chemotherapeutic agents. Consistently, these molecules are
exquisitely potent (GI50o10nM; GI is the drug concentration that
inhibits cell growth by 50%) against a specific subset of human
cancer cell lines in the National Cancer Institute (NCI) in vitro
anticancer drug screen, producing highly characteristic mean
graph patterns.
2-(4-Amino-3-methylphenyl)benzothiazole (DF 203, NSC
674495) and 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole
(5F 203, NSC 703786) are efficiently sequestered by sensitive cell
lines (e.g. breast MCF-7, MDA-468; renal TK-10) (Chua et al,
1999a,b; Kashiyama et al, 1999). In stark contrast, insensitive cell
lines (GI50410mM, e.g. breast MDA-MB-435; renal A498, CAKI-1;
prostate PC-3) fail to deplete these agents from nutrient media.
Planar, hydrophobic aminophenylbenzothiazole analogues are
potent agonists for the aryl hydrocarbon receptor (AhR). Nuclear
translocation follows high affinity (nM) binding IC50 between
ligand and cytosolic AhR. Xenobiotic response element (XRE)-
driven luciferase activity is induced and protein–DNA complexes
are formed on the XRE sequence of the cytochrome P450 (CYP)
1A1 promoter (Loaiza-Perez et al, 2002). Thus, CYP1A1 mRNA
activity and protein expression are induced exclusively in sensitive
cell lines (Chua et al, 2000).
Crucially, induction of CYP1A1-catalysed biotransformation of
2-(4-aminophenyl)benzothiazoles within tumour cells is essential
for drug activation. Covalent binding, detected between DF 203
and recombinant CYP1A1, requires metabolism and is signifi-
cantly reduced by glutathione, suggesting the formation of an
electrophilic, reactive intermediate species. Paradoxically, the C-6
hydroxylated biotransformation product, liberated into nutrient
media of cells exposed to DF 203, is devoid of antitumour activity;
moreover, this metabolite is able to antagonise cellular uptake of
DF 203, covalent binding between CYP1A1 and DF 203, CYP1A1
activity and growth inhibition induced by DF 203 (Hutchinson
et al, 2001).
Using ab initio frontier molecular orbital (FMO) calculations,
the presence or absence of exportable hydroxy metabolites of
fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles can be
predicted (O’Brien et al, in press). Only the 5-fluoro isomer
produced a conventional dose–response following treatment
of cells; indeed, oxidative metabolism at C-6 was eradicated.
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sThus, 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203,
NSC 703786) is the favoured analogue for clinical consideration
possessing enhanced efficacy in vitro and superior potency in vivo
against human breast and ovarian tumour xenografts implanted
in nude mice (Hutchinson et al, 2001; Bradshaw et al, 2002a).
The lysylamide dihydrochloride salt of 5F 203 (Phortress, NSC
710305) has been derivatised at the exocyclic primary amine
function fulfilling the criteria for a suitable prodrug. It is
water soluble, chemically stable, pharmaceutically robust and
undergoes rapid, quantitative bioreversion to the parent moiety
in vitro and in vivo (Bradshaw et al, 2002a,b; Hutchinson et al,
2002) (Figure 1).
Additionally, a putative, as yet undefined, role of CYP1B1 in the
mechanism of action of aminophenylbenzothiazoles has been
implicated. CYP1B1 microsomes are able to metabolise DF 203,
and modulation of CYP1B1 expression in sensitive cell lines has
been observed in response to benzothiazole treatment as well as
induction of CYP1B1 mRNA in MCF-7 cells. The CYPs comprise a
superfamily of haemoproteins that catalyse the initial mono-
oxygenation of a range of lipophilic endogenous, environmental or
dietary xenobiotic substrates (Guengerich, 1992; Crofts et al, 1998).
The substrate specificities of CYP1A1 and CYP1B1 overlap: both
isoforms are important in the metabolism of polycyclic aromatic
hydrocarbons (PAHs) and some heterocyclic amines (Shimada
et al, 1996, 1998).
We have examined the hypothesis that exposure to analogues
of this unique class of antitumour agent selectively generates
benzothiazole-derived covalent DNA adducts in sensitive
cell lines. The powerful
32P-postlabelling technique has been
adopted for the detection of DNA adducts (Martin et al,
1997, 1998).
Optimisation of the procedure for detection and separation of
benzothiazole-DNA adducts preceded in vitro studies to investi-
gate time- and dose-dependent accumulation of 5F 203-DNA
adducts in MCF-7 mammary carcinoma cells. 5F 203-derived
adducts have been compared with DNA adduct formation in MCF-
7 and IGROV-1 ovarian carcinoma cells following treatment with
Phortress. We demonstrate selective generation of adducts in the
DNA of sensitive tumour cells in vitro and disclose chromato-
graphically equivalent adduct formation in vivo in MCF-7 and
IGROV-1 xenografts, following treatment of mice, i.p. with
Phortress (20mgkg
 1).
MATERIALS AND METHODS
Cell culture
Human-derived carcinoma cell lines (MCF-7, MDA-MB-435 breast,
HCT 116 colon and IGROV-1 ovarian) were cultured in RPMI-1640
medium supplemented with 10% FBS. Cells were subcultivated
twice weekly to maintain logarithmic growth. Amines were
prepared in DMSO as a 10mM stock. Phortress was prepared in
medium immediately prior to use. Cells were seeded at the
appropriate density and, after 24h, nutrient media refreshed and
drug introduced. Following the desired exposure period, cells were
harvested by trypsinisation, washed in PBS and counted.
In vivo procedure
UKCCCR guidelines for the welfare of animals in experimental
neoplasia were adhered to during all in vivo studies. MCF-7, MDA-
MB-435 breast and IGROV-1 ovarian xenografts were transplanted
s.c. into flanks of NCR-Nu female nude mice. Animals were treated
i.p. with 20mgkg
 1 Phortress (n¼4) or vehicle alone (saline).
Pellets (60 day release 17b-estradiol, 0.72mgpellet
 1: Innovative
Research, USA) were implanted s.c. in mice bearing MCF-7
xenografts maintaining blood levels of 300–400pgml
 1. Following
24h exposure, tumours were removed and snap frozen ( 801C).
To examine the selective nature of DNA adduct formation in vivo,
mice bearing MCF-7 and MDA-MB-435 tumours in opposite flanks
were treated with Phortress. After 24h treatment, animals were
killed. Tumours were recovered and snap frozen.
Determination of DNA adducts
DNA was extracted from cells or xenograft tissue using Qiagen
DNA extraction columns (Qiagen, Crawley, UK) as described in
the manufacturer’s instructions. DNA was dissolved in 0.5–1ml of
1:100 SSC (0.015 M sodium citrate, 0.15 M NaCl, pH 7.2) and
absorbance recorded at 230, 260, 280 and 320nm using a UV
spectrometer. The quantity of DNA was calculated from the
absorbance at 260nm assuming that an absorbance value of 1 is
equivalent to a DNA concentration of 50mgml
 1. The purity of the
extracted DNA was determined from the 260/280nm absorbance
ratio. DNA with a ratio 41.7 was considered pure.
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Figure 1 Structures of (A) 2-(4-amino-3-methylphenyl)benzothiazole (R¼H; DF 203; NSC 674495), 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole
(R¼F; 5F 203, NSC 703786) and (B) the lysylamide dihydrochloride salt of 5F 203 (Phortress, NSC 710305).
Figure 2 TLC phosphorimager images of
32P-postlabelled DNA from MCF-7 (B and D) and HCT 116 (A and C) cell lines, untreated (A and B) and
following exposure to DF 203 (1mM 72h, C and D).
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sDNA was dried and hydrolysed to deoxynucleoside 30-mono-
phosphates by incubating 5mg of DNA with micrococcal nuclease
(175mU), calf-spleen phosphodiesterase (3mU) in 1ml of SSCC
(100mM sodium succinate, pH 6.0: 50mM CaCl2) and d-H2Ot oa
total volume of 6.25ml. The mixture was incubated at 371C
overnight.
Adducts were enriched by butanol extraction. Digested
DNA (5mg) was diluted with 115ml HPLC-grade water. To
each sample, 100mM ammonium formate (15ml, pH 3.5) and
10mM tetrabutylammonium chloride (TBAC) (15ml) were
added. The mixture was extracted twice with water saturated
1-butanol. The combined organic phase was back-extracted
twice with 250ml butanol saturated water to remove trace
contaminants of normal nucleotides. The butanol extract was
then neutralised by the addition of 3ml 200mM Tris HCl
(pH 7.6) and evaporated in a Speed Vac Concentrator (Savant
Instruments, Inc., Hickville, NY, USA). Radiolabelling was
achieved by incubating adducted nucleotides from 5mg DNA
with T4 polynucleotide (6.25 units) and 62.5mCi [g
32P]ATP for 1h
at 371C.
The
32P-labelled products were diluted to 100ml with HPLC-
grade water. The solution was injected onto a Hypersil ODS C18
analytical column (250 4.6mm, 5mM; Shandon), eluted at a flow
rate of 1.0mlmin
 1 with 2 M ammonium formate (pH 4.0) (A)
and acetonitrile (B). HPLC gradient: 88% (vv
 1) A initial
mixture, 50min linear gradient to 75% A followed by 15min
linear gradient to 55% A. The radioactivity was monitored by a
radiochemical detector (Lab Logic, b-RAM, Sheffield) lined to a
Varian Star 9012 pump. Data analysis was by Laura (MS Windows
package, Lab Logic Inc, Sheffield).
For quantification of the adduct levels, known amounts of
[g-
32p] ATP were injected onto the HPLC, peaks were collected and
radioactivity was measured in disintegrations per min (dpm) by
scintillation counting. ATP peak area was plotted against dpm to
give a standard curve. For subsequent analyses, HPLC peak areas
were measured and values were applied to this standard curve to
give values in dpm. Relative adduct levels (RAL) were calculated
according to Reddy and Randerath (1986) and translated into fmol
adducts per mg DNA by multiplying RAL 10
7 0.3240 (Gupta,
1985). The specific activity of [g-
32P]ATP was corrected by
calculating the extent of decay.
Preliminary studies included enrichment of adducts by
nuclease P1-catalysed dephosphorylation, exploiting the ability
of certain bulky adducts to protect the nucleotide from digestion
by nuclease P1 and the absolute requirement of the 30 phosphate
in the subsequent labelling step (transfer of g-
32P from
32P-ATP
to the 50 position of the nucleotides by the enzyme T4
polynucleotide kinase to give 30,5 0-bisphosphates). In addition
to HPLC analyses, adducted DNA was separated by thin
layer chromatography (TLC) in two directions on 10 10cm
PEI-cellulose TLC plates. Samples were spotted in the lower
left corner of each plate and run from top to bottom in 2.3 M
sodium phosphate, pH 5.8, onto an attached wick. After
washing and drying, the plates were developed from bottom
to top in 2.79 M lithium formate, 4.95 M urea, pH 3.4. The
final chromatographic washes were run at 901 (left to right) in
0.75 M sodium dihydrogenhosphate, 0.45 M Tris, 8.0 M urea,
pH 8.2 and then 1.7 M sodium phosphate, pH 6.0 onto an
attached wick.
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Figure 3 Radiochromatograms of
32P-postlabelled DNA adducts in
DNA of MCF-7 cells following incubation with (A) medium alone, (B)
10nM,( C) 100nM,( D)1mM and (E)1 0mM 5F 203 for 72h. Adducts were
enriched by butanol extraction prior to postlabelling and separated by
HPLC. Note the y scale of chromatograms for control, 10 and 100nM is
1000 c.p.m. while the scale for 1 and 10mM is 20000 c.p.m. to aid
resolution of the adduct profile.
0
1000
2000
3000
4000
5000
Control 2 6 24 48 72
Exposure time (hour)
A
d
d
u
c
t
s
 
/
 
1
0
8
 
n
u
c
l
e
o
t
i
d
e
s
Figure 4 Accumulation of DNA adducts in MCF-7 cells in vitro, treated
with 1mM 5F 203. Following extraction of DNA, adducts were enriched by
butanol extraction,
32P-postlabelled and separated by HPLC. Bars, s.d.
(nX3).
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In vitro
Preliminary studies clearly demonstrated DNA adduct formation
in sensitive cells only (e.g. MCF-7, MDA 468 human mammary
carcinoma cell lines) following their exposure to DF 203,
irrespective of the analytical method adopted (Stevens et al,
2001). Enrichment of adducts by butanol extraction or nuclease P1
digestion prior to adduct separation by TLC (Figure 2) or HPLC
unequivocally demonstrated the formation of one major and a
number of minor adducts in the DNA of MCF-7 cells after drug
treatment (1mM DF 203, 72h). Insensitive HCT 116 cells incurred
negligible DNA damage. The chromatographic profile of DNA
adducts in MDA 468 cells was identical to that generated in MCF-7
cells (result not shown). No adducts were detected in HPLC traces
of untreated cells.
It was concluded that butanol extraction prior to quantitative
HPLC separation of benzothiazole-derived adducts was the
protocol most suitable for their detection using the
32P-postlabel-
ling technique.
5F 203 dose response
MCF-7 mammary carcinoma cells were exposed to concentrations
of 5F 203 between 10nM and 10mM for 72h before DNA was
extracted, adducted nucleotides enriched and adduct levels
determined by HPLC (Figure 3). Following exposure of cells to
10nM 5F 203, very few adducts were detected. 5F 203-derived DNA
adducts (labelled 2, 9 and 10) were separated after treatment of
cells with 100nM drug. 1mM 5F 203 effected considerable adduct
formation; 1 major adduct, 9, and a number of minor adducts (e.g.
represented by peaks 2 and 10) were evident. Following treatment
of cells with 10mM 5F 203, the total number of adducts increased;
strikingly, the major adduct had become adduct 2 (Figure 3E).
Adducts (represented by peak 9) increased only slightly.
Accumulation of DNA adducts with time
After only 2h treatment (1mM 5F 203) adducts could be detected in
the DNA of MCF-7 cells. Accumulation of DNA adducts was
evident up to 24h exposure, at which point potential for further
adduct formation appeared saturated (Figure 4).
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Figure 5 HPLC separation of butanol-extracted,
32P-postlabelled DNA adducts in MCF-7 (A and B), MDA-MB-435 (C and D) and IGROV-1 (E and F)
cells following exposure to 1mM (A, C and E) and 10mM Phortress (B, D and F) in vitro. MCF-7 and MDA-MB-435 cells were exposed to drug for 72h.
DNA adducts generated in IGROV-1 cells were analysed after 24h treatment.
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vitro
Adducts were detected in the DNA of MCF-7 and IGROV-1 cells
exposed to concentrations of Phortress X100nM:1 mM Phortress
induced one major and a number of minor adducts (Figure 5).
However, adduct profiles in these two cell lines were not identical:
peaks equivalent to adducts 14 and 15 in the DNA of MCF-7 cells
were absent in DNA extracted from IGROV-1 cells exposed to 1mM
Phortress. MCF-7 cells received 72h Phortress exposure, whereas
after this length of time Phortress was lethal to IGROV-1 cells.
Thus, DNA adduct accumulation was analysed in IGROV-1 cells
after 24h exposure to Phortress. The profile and number of DNA
adducts in DNA isolated from IGROV-1 cells do not differ
significantly whether exposed to 1 or 10mM Phortress. However,
following treatment of MCF-7 cells with 10mM Phortress, a new
major adduct emerged (peak 13). Significantly, the DNA of MDA-
MB-435 cells treated with Phortress (72h, 10nM–10mM) remained
free from Phortress-derived adducts.
Generation of Phortress-derived DNA adducts in vivo
Mice bearing sensitive MCF-7, IGROV-1 and inherently resistant
MDA-MB-435 tumours s.c. in the flank were treated with
20mgkg
 1 Phortress or vehicle alone (i.p.). Guided by in vitro
data (Figure 4) and the knowledge that CYP1A1 protein can clearly
be detected within sensitive xenografts 24h post-treatment
(Bradshaw et al, 2002a), tumours were recovered 24h after animals
were treated and DNA extracted. HPLC detection of
32P-
postlabelled adducts clearly distinguished one major and a number
of minor Phortress-derived adducts in the DNA of MCF-7
xenografts (Figure 6). As the technique is quantitative, it can be
seen that the number and diversity of adducts sustained in
IGROV-1 tumours is significantly less than the number of
Phortress-derived DNA adducts detected in MCF-7 xenografts.
No adducts were detected in MDA-MB-435 DNA.
Data shown in Figure 7 demonstrate that Phortress-derived
adducts in vivo co-chromatograph with adducts formed by 5F 203
in vitro. The retention time of the major adduct detected in MCF-7
tumours of Phortress-treated mice was identical to that seen
following treatment of MCF-7 cells in vitro with 5F 203. Adducts
20, 21 and 22 formed in MCF-7 xenografts of mice treated with a
single dose of 20mgkg
 1 Phortress (24h) were found to coelute
with adducts 2, 6 and 9 derived from MCF-7 cells exposed to 1mM
5F 203 (72h).
Mice bearing sensitive MCF-7 tumours in one flank and
inherently resistant MDA-MB-435 tumours in the opposite flank
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Figure 6 HPLC separation of
32P-postlabelled adducts of control MCF-7 (A), MDA-MB-435 (C) and IGROV-1 (E) xenografts from untreated animals
and MCF-7 (B), MDA-MB-435 (D) and IGROV-1 (F) xenografts from mice treated with 20mgkg
 1 Phortress i.p. Tumours were recovered 24h post-
treatment.
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 1 Phortress. After 24h, animals
were killed and tumours were prepared for analysis of DNA
adducts. The specificity for DNA adduct formation in sensitive
tumours only is unequivocally observed (Figure 8). Numbers of
adducts detected in MCF-7 xenografts did not differ significantly
from those previously detected (260780 10
 8 nucleotides).
DISCUSSION
In this study, we have examined the hypothesis that DNA adduct
formation may be the biochemical sequel to CYP-mediated
metabolic production of putative electrophilic species derived
from antitumour 2-(4-aminophenyl)benzothiazoles. It is proposed
that the generation of covalent adducts in sensitive cells precedes
the exquisitely selective cell death ensuing exposure, in vitro and
in vivo, to analogues of this distinct class of antitumour agent.
In vitro, sensitivity correlates with induction of CYP1A1
mRNA, activity and protein expression. Engagement of apoptotic
machinery (induction of apoptosis-initiating receptor CD95/FAS1,
upregulation of P53 and P21, downregulation of Bcl-2; Monks et al,
2001; Chua et al, 1999a,b) and detection of DNA single-strand
breaks has been observed in responsive mammary carcinoma
cells when challenged with benzothiazole analogues (Bradshaw
et al, 2000).
Selective generation of DNA adducts in cell lines (MCF-7,
IGROV-1) sensitive to 2-(4-aminophenyl)benzothiazole analogues
(DF 203, 5F 203, Phortress) has been demonstrated, whereas
negligible adduct formation was detected in DNA of inherently
resistant HCT 116 colon (Figure 2) and MDA-MB-435 breast
carcinoma cells.
Few adducts could be detected in the DNA of sensitive (MCF-7,
IGROV-1) cells exposed to concentrations of 5F 203 or Phortress
o100nM. Evidence supports the supposition that DNA repair
mechanisms are employed: human damage-specific DNA-binding
protein (DDB) mRNA is significantly upregulated in sensitive
MCF-7 cells after benzothiazole treatment. DDB, a heterodimer of
48 and 127kDa subunits, possesses a role in DNA repair and is
upregulated in response to UV-induced lesions (Nichols et al,
2000). Moreover, DDB activity is absent from a subset of
xeroderma pigmentosum (XP) patients possessing a phenotype
of defective excision repair (Zolezzi and Linn, 2000). In addition
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Figure 7 HPLC radiochromatograms of
32P-postlabelled adducts. (A)
DNA (5mg) from MCF-7 xenograft of Phortress-treated (20mgkg
 1, i.p.)
mouse. (B) DNA (0.5mg) from MCF-7 cells treated with 1mM 5F 203 for
72h. (C) Coelution of A and B.
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Figure 8 Analysis of DNA adduct formation in tumour xenografts implanted s.c. in opposite flanks of the same mouse recovered 24h after Phortress
treatment (20mgkg
 1, i.p.). (A) MCF-7. (B) MDA-MB-435.
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Figure 9 Putative electrophilic reactive intermediates derived from
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ionising radiation (Fiscella et al, 1997), is also upregulated
following benzothiazole treatment. Alternatively, nucleophilic
sequestration of low concentrations of reactive intermediates by
cellular peptides (e.g. glutathione) or proteins may occur at low
drug concentrations. At 1mM 5F 203 a clear adduct profile emerges
in DNA of MCF-7 cells revealing one major and a number of minor
adducts. Intriguingly, and emphatically at 10mM, a new major
adduct, 2, dominates. In MCF-7 cells treated with 10mM Phortess,
the previously minor peak 13, analogous to the 5F 203-generated
peak 2, becomes an emerging major adduct. This phenomenon
fails to occur in IGROV-1 cells whose capacity for adduct burden
appears saturated at 1mM. We may speculate that CYP1A1 and
CYP1B1 effect the formation of distinct 5F 203-derived adducts
and moreover that CYP1A1- and CYP1B1-induced adducts are
generated by exposure to different benzothiazole concentrations.
In IGROV-1 cells, CYP1B1 protein expression was not constitutive
and only negligibly induced by 5F 203 (1mM,1 0mM) (Hose et al,i n
press). In MCF-7 cells, constitutively expressed CYP1B1 is further
induced by 2-(4-aminophenyl)benzothiazole concentrations ex-
ceeding 3mM concurring with the emergence of major adduct 2 (5F
203) or 13 (Phortress). EROD activity and CYP1A1 expression are
maximally induced in cells treated with 1mM 2-(4-aminophenyl)-
benzothiazoles concurring with the apparent saturation of adduct
9 (5F 203, MCF-7 cells), 16 (Phortress, MCF-7 cells) or 19
(Phortress, IGROV-1 cells). Indeed, concentrations 41mM result
in irreversible inhibition of CYP1A1 activity (Chua et al, 2000).
In V79 cells stably expressing either CYP1A1 or CYP1B1
enzymes, significantly lower concentrations of dibenzo[a,l]pyrene
are required before the formation of the highly carcinogenic
CYP1B1-dependent ( )-anti-dibenzo[a,l]pyrene diol epoxide
(DB[a,l]PDE) adducts (Luch et al, 1998). In addition, CYP
regioselectivity towards the endogenous hormone 17b-oestradiol
has been demonstrated; 1A1 catalyses 2-hydroxylation, whereas
CYP1B1 is a highly selective oestradiol 4-hydroxylase.
Generation of 5F 203-derived adducts over time (Figure 4)
correlated precisely with induction of CYP1A1 transcription and
EROD activity in MCF-7 cells treated with 2-(4-amino-3-methyl-
phenyl)benzothiazoles. In vitro, adduct accumulation occurred
maximally by 24h.
Significant DNA adducts were detected in MCF-7 tumour
xenografts 24h after treatment of mice with a concentration of
Phortress known to elicit antitumour activity (Bradshaw et al,
2002a). Phortress (2 20mgkg
 1, i.p.), administered weekly,
inhibited the growth of these tumours by 68% (vv
 1). In
IGROV-1 tumours of treated mice, where Phortress administered
on the same schedule inhibited xenograft growth by 50%, fewer
DNA adduct species were separated; moreover, adducts, whose
profile was chromatographically equivalent to that of MCF-7
tumours, were significantly fewer (Figure 6). Negligible adducts
were generated in inherently resistant MDA-MB-435 tumours.
Thus, adduct burden concurs exactly with the sensitivities of these
three xenografts to Phortress. We suggest that in human IGROV-1
xenografts, the major Phortress-derived DNA adduct 24 is
equivalent to adduct 22 in MCF-7 tumours. In vitro, equivalent
Phortress-generated adduct species are represented by peaks 16
and 19 in MCF-7 and IGROV-1 cells, respectively. In MCF-7 cells,
Phortress-derived adducts represented by peaks 13 and 16
(Figure 5) are equivalent to 5F 203-generated adducts 2 and 9
(Figure 3). Evidence confirming that a major adduct is commonly
induced in vitro and in vivo by 5F 203 and its lysylamide prodrug
has been obtained. DNA extracted from MCF-7 cells exposed to 5F
203 (1mM, peak 9) and MCF-7 xenograft tissue of a mouse exposed
to Phortress (peak 22) coelute, demonstrating the generation of
identical adduct species.
The exquisite specificity of Phortress-derived adduct generation
has been corroborated, following treatment of mice bearing
sensitive MCF-7 and inherently resistant MDA-MB-435 tumours
in opposite flanks (Figure 8). Thus, tumour sensitivity has been
predicted accurately: in antitumour tests, the growth of MCF-7
xenografts was significantly retarded whereas MDA-MB-435
tumours transplanted in the opposite flank continued to grow
(Bradshaw et al, 2002a). Thus, we propose that the evaluation of
DNA adduct formation may provide a valuable pharmacodynamic
(PD) end point predictive of tumour sensitivity.
Phortress effects an exquisitely selective antitumour response
via a mechanism of action distinct from any clinically used
chemotherapeutic agent. It is cleaved in the presence of tumour
cells to yield 5F 203, which remains inertly in the milieu of cells
immune to this agent. However, once in the presence of a sensitive
cancer cell, a cascade of events is initiated resulting in the
induction of CYP1A1-catalysed metabolism of 5F 203. Generation
of adducts between electrophilic reactive intermediates of 5F 203
and DNA exacts lethal damage that precedes cell death.
FMO calculations predict that a reactive electrophilic nitrenium
species may be implicated in the generation of DNA adducts
(O’Brien et al, in press). Structures of a nitrenium species and
p-carbocation mesomeric forms derived from 5F 203 are shown in
Figure 9. These structures infer that nucleophilic centres in DNA
bases might become adducted at the exocyclic nitrogen (via A), or
at carbon atoms in the 2-aryl group (B) or the benzothiazole
moiety (C; Stevens et al, 1996). This could explain the multiplicity
of adducts observed in sensitive tumour cells such as MCF-7
(Figure 3E). We are currently attempting to identify the structures
of these adducts to determine why they are so damaging to
sensitive tumour cells.
In conclusion, Phortress offers the opportunity for introduction
into the clinic of a novel and selective antitumour agent. The
techniques described present potential for the measurement of a
clearly defined PD end point.
Phortress will undergo clinical evaluation under the auspices of
Cancer Research UK and Phase I trials are due to begin in 2003.
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